• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

欧洲生物分析论坛关于在抗药物抗体检测中建立适当药物宽容度水平的建议。

The European Bioanalysis Forum recommendation on establishing appropriate drug tolerance levels in antidrug antibody assays.

机构信息

Merck KGaA, Research & Development, Drug Metabolism & Pharmacokinetics New Biological Entities, Darmstadt, 64293, Germany.

Celerion Switzerland AG, Bioanalytical Services, Fehraltorf, 8320, Switzerland.

出版信息

Bioanalysis. 2024;16(17-18):915-921. doi: 10.1080/17576180.2024.2376950. Epub 2024 Aug 5.

DOI:10.1080/17576180.2024.2376950
PMID:39101618
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11485778/
Abstract

The European Bioanalysis Forum, in collaboration with several key industry stakeholders, has recently led discussions that address international immunogenicity guidance documents, specifically the three tier approach for immunogenicity testing strategies, after more than 20 years of experience with biotherapeutics. As part of this, the strategy and methods used to assess drug tolerance across all immunogenicity assays are challenged, emphasizing that bioanalytical scientists need to consider the context-of-use of each assay. Here, recommendations for drug tolerance assessments, driven by strong scientific rationale and subject to reevaluation as needed, are provided. This includes carefully considering the drug and positive control concentrations considered to be appropriate and which tiers are most relevant for performing drug tolerance assessments.

摘要

欧洲生物分析论坛(European Bioanalysis Forum)与多个主要行业利益相关者合作,最近对国际免疫原性指导文件进行了讨论,特别是针对免疫原性检测策略的三层方法,这是在具有 20 多年生物治疗经验之后进行的。作为其中的一部分,用于评估所有免疫原性检测中药物耐受性的策略和方法受到了挑战,强调生物分析科学家需要考虑每个检测的使用情况。在这里,根据强有力的科学原理提供了药物耐受性评估的建议,并根据需要进行重新评估。这包括仔细考虑被认为合适的药物和阳性对照浓度,以及进行药物耐受性评估最相关的层次。

相似文献

1
The European Bioanalysis Forum recommendation on establishing appropriate drug tolerance levels in antidrug antibody assays.欧洲生物分析论坛关于在抗药物抗体检测中建立适当药物宽容度水平的建议。
Bioanalysis. 2024;16(17-18):915-921. doi: 10.1080/17576180.2024.2376950. Epub 2024 Aug 5.
2
Health professionals' experience of teamwork education in acute hospital settings: a systematic review of qualitative literature.医疗专业人员在急症医院环境中团队合作教育的经验:对定性文献的系统综述
JBI Database System Rev Implement Rep. 2016 Apr;14(4):96-137. doi: 10.11124/JBISRIR-2016-1843.
3
Sexual Harassment and Prevention Training性骚扰与预防培训
4
2024 White Paper on Recent Issues in Bioanalysis: Evolution of Immunogenicity Assessment beyond ADA/NAb; Regulated Genomic/NGS Assays; Hypersensitivity Reactions; Minimum Noise Reduction; False Positive Range; Modernized Vaccine Approaches; NAb/TAb Correlation - Recommendations on Advanced Strategies for Molecular Assays and Immunogenicity of Gene Therapy, Cell Therapy, Vaccine; Biotherapeutics Immunogenicity Assessment & Clinical Relevance - Regulatory Agencies' Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell & Vaccine Therapies).2024年生物分析近期问题白皮书:超越ADA/NAb的免疫原性评估演变;规范的基因组/NGS检测;超敏反应;最小降噪;假阳性范围;现代化疫苗方法;NAb/TAb相关性——基因治疗、细胞治疗、疫苗分子检测和免疫原性的先进策略建议;生物治疗药物免疫原性评估与临床相关性——监管机构对生物治疗药物、基因、细胞和疫苗治疗的免疫原性/技术的意见)
Bioanalysis. 2025 Feb;17(3):105-149. doi: 10.1080/17576180.2024.2439229. Epub 2025 Jan 25.
5
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
6
Systemic Inflammatory Response Syndrome全身炎症反应综合征
7
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
8
Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline.不宁腿综合征和周期性肢体运动障碍的治疗:美国睡眠医学学会临床实践指南
J Clin Sleep Med. 2025 Jan 1;21(1):137-152. doi: 10.5664/jcsm.11390.
9
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].[支气管哮喘防治指南(2024年版)]
Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601.
10
Thrombolysis for acute ischaemic stroke.急性缺血性脑卒中的溶栓治疗
Cochrane Database Syst Rev. 2003(3):CD000213. doi: 10.1002/14651858.CD000213.

引用本文的文献

1
Recent discussions and proposals on challenging the 3-tier immunogenicity testing strategies from the European bioanalysis forum.欧洲生物分析论坛近期关于挑战三层免疫原性检测策略的讨论与提议。
Bioanalysis. 2025 May;17(9):575-578. doi: 10.1080/17576180.2025.2487377. Epub 2025 Apr 9.

本文引用的文献

1
Re-thinking the current paradigm for clinical immunogenicity assessment: an update from the discussion in the European Bioanalysis Forum.重新思考当前临床免疫原性评估的范式:欧洲生物分析论坛讨论的更新。
Bioanalysis. 2024;16(17-18):905-913. doi: 10.1080/17576180.2024.2376949. Epub 2024 Aug 9.
2
A European Bioanalysis Forum recommendation for requiring a context-of-use statement for successful development and validation of biomarker assays.一份关于成功开发和验证生物标志物检测方法需要使用情况说明的欧洲生物分析论坛建议。
Bioanalysis. 2024;16(16):835-842. doi: 10.1080/17576180.2024.2376436. Epub 2024 Aug 5.
3
Selection of positive controls and their impact on anti-drug antibody assay performance.阳性对照品的选择及其对抗体药物检测性能的影响。
J Immunol Methods. 2024 May;528:113657. doi: 10.1016/j.jim.2024.113657. Epub 2024 Mar 11.
4
Anti-drug Antibody Magnitude and Clinical Relevance Using Signal to Noise (S/N): Bococizumab Case Study.抗药物抗体幅度和使用信号噪声比(S/N)的临床相关性:Bococizumab 案例研究。
AAPS J. 2023 Sep 2;25(5):85. doi: 10.1208/s12248-023-00846-x.
5
Assay development considerations to improve drug tolerance in direct competitive ligand binding neutralizing antibody assays, pretreatment strategies.提高直接竞争配体结合中和抗体测定法药物耐受性的分析方法开发考虑因素,预处理策略。
J Immunol Methods. 2023 Jun;517:113484. doi: 10.1016/j.jim.2023.113484. Epub 2023 Apr 26.
6
Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.在复发或难治性 B 细胞非霍奇金淋巴瘤患者中,帕洛昔单抗维地滨的免疫原性综合总结。
Front Immunol. 2023 Mar 29;14:1119510. doi: 10.3389/fimmu.2023.1119510. eCollection 2023.
7
A Novel Neutralization Antibody Assay Method to Overcome Drug Interference with Better Compatibility with Acid-Sensitive Neutralizing Antibodies.一种克服药物干扰的新型中和抗体检测方法,与酸性敏感中和抗体具有更好的兼容性。
AAPS J. 2023 Jan 25;25(1):18. doi: 10.1208/s12248-023-00783-9.
8
Biomarker context-of-use: how organizational design can impact the implementation of the appropriate biomarker assay strategy.生物标志物应用场景:组织设计如何影响适当的生物标志物检测策略的实施。
Bioanalysis. 2022 Jul;14(13):911-917. doi: 10.4155/bio-2022-0143. Epub 2022 Jul 29.
9
Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium.利用行业联盟的临床数据比较用于测定抗药物抗体水平的滴度和信噪比(S/N)
AAPS J. 2022 Jul 12;24(4):81. doi: 10.1208/s12248-022-00728-8.
10
Anti-drug Antibody Validation Testing and Reporting Harmonization.抗药物抗体验证测试和报告的协调统一。
AAPS J. 2021 Dec 1;24(1):4. doi: 10.1208/s12248-021-00649-y.